ArticleClinicoEconomics and outcomes research : CEOR2025
Beyond the COVID-19 Pandemic: Budget Impact Analysis of Remote Healthcare Delivery for Hypertension and Diabetes Mellitus Management in Thailand.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The COVID-19 pandemic disrupted healthcare services globally, necessitating innovative care delivery models for non-communicable diseases. Remote healthcare pathways, including telehealth with pharmacy at home (PAH) and deferred care (DC), emerged as potential solutions for managing stable hypertension (HT) and diabetes mellitus (DM) patients. This study aims to estimate the budget impact of implementing PAH and DC compared to usual care (UC) for HT and DM patients in Thai tertiary care hospitals from the government perspective. Methods: A retrospective budget impact analysis was conducted using data from July-December 2021 (COVID-19 period) and July-December 2022 (new normal period). The study included stable patients from 35 tertiary care hospitals in Thailand. Direct medical costs were obtained from administrative databases and national costing studies. Multivariate log-linear regression models estimated conditional costs, controlling for patient characteristics. The analysis compared baseline scenario (UC only) versus alternative scenario (UC+PAH+DC). Sensitivity analyses were performed using 95% confidence intervals and ±20% population variations. Results: The alternative scenario demonstrated lower total budgets in both periods. During COVID-19, total costs were 12.23 versus 12.94 million USD (baseline), yielding 0.71 million USD in savings. In the new normal, costs were 11.93 versus 12.54 million USD (baseline), generating 0.61 million USD in savings. Cost-saving ratios were 0.06 USD and 0.05 USD per dollar allocated during the COVID-19 and new normal periods, respectively. Sensitivity analyses confirmed robustness across parameter variations. Conclusion: PAH and DC pathways represent economically advantageous alternatives, demonstrating cost savings from the government perspective. These findings support implementing remote healthcare delivery in resource-constrained settings, though comprehensive evaluations incorporating societal and patient perspectives are warranted. The findings are based on extrapolation-based results and should be interpreted with caution due to variability in parameters including adoption rates of PAH/DC, unit costs applied, patient numbers, retrospective design, bundled interventions, and the savings ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.